NCT04613674 2024-03-27
A Study of Camrelizumab Plus Chemotherapy vs Placebo Plus Chemotherapy as Neoadjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC)
Jiangsu HengRui Medicine Co., Ltd.
Phase 3 Completed
Clinical Trials
4 trialsNCT04335006 2023-05-06
A Phase 3 Study Comparing Carelizumab Plus Nab-paclitaxel and Apatinib, Carelizumab Plus Nab-paclitaxel, and Nab-paclitaxel in Patients With Advanced Triple Negative Breast Cancer.
Jiangsu HengRui Medicine Co., Ltd.
Phase 3 Terminated
NCT02742935 2023-02-27
A Study to Evaluate the Safety and Tolerability of Using SHR-1210 by Advanced Solid Tumor Subjects
Jiangsu HengRui Medicine Co., Ltd.
Phase 1 Completed
NCT03945604 2022-08-12
A Trial of SHR-1210 (an Anti-PD-1 Inhibitor) in Combination With Apatinib and Fluzoparib in Patients With TNBC
Jiangsu HengRui Medicine Co., Ltd.
Phase 1 Completed